Pneumovax 23

Χώρα: Σιγκαπούρη

Γλώσσα: Αγγλικά

Πηγή: HSA (Health Sciences Authority)

Δραστική ουσία:

PNEUMOCOCCAL POLYSACCHARIDES 23 MOST PREVALENT TYPES

Διαθέσιμο από:

MSD PHARMA (SINGAPORE) PTE. LTD.

Φαρμακολογική κατηγορία (ATC):

J07AL01

Δοσολογία:

25mcg/0.5ml each

Φαρμακοτεχνική μορφή:

INJECTION

Σύνθεση:

PNEUMOCOCCAL POLYSACCHARIDES 23 MOST PREVALENT TYPES 25mcg/0.5ml each

Οδός χορήγησης:

INTRAMUSCULAR

Τρόπος διάθεσης:

Prescription Only

Κατασκευάζεται από:

MERCK SHARP & DOHME LLC

Καθεστώς αδειοδότησης:

ACTIVE

Ημερομηνία της άδειας:

1988-06-24

Φύλλο οδηγιών χρήσης

 
SG-V110-I- 032013

PHYSICIANS CIRCULAR 

Injection 
PNEUMOVAX
®
 23 
(pneumococcal vaccine, polyvalent, MSD)  

PNEUMOVAX 23 (pneumococcal vaccine, polyvalent, MSD),
is a sterile, liquid vaccine for intramuscular or 
subcutaneous injection. It consists of a mixture of highly purified
capsular polysaccharides from the 23 most 
prevalent or invasive pneumococcal types of _Streptococcus
pneumoniae_, including the six serotypes that 
most frequently cause invasive drug-resistant pneumococcal
infections among children and adults in the 
United States (see Table 1). The 23-valent vaccine accounts for at
least 90% of pneumococcal blood 
isolates and at least 85% of all pneumococcal isolates from sites
which are generally sterile as determined 
by ongoing surveillance of United States data. 

PNEUMOVAX 23 is manufactured according to methods developed by the
MERCK RESEARCH 
LABORATORIES. Each 0.5 mL dose of vaccine contains 25 mcg of each
polysaccharide type dissolved in 
isotonic saline solution containing 0.25% phenol as a preservative.  

Table 1 
23 Pneumococcal Capsular Types Included in PNEUMOVAX 23

Danish Nomenclature 
Pneumococcal Types
1 2 3  4 5  6B** 7F 8  9N  9V**  10A 
11A 12F  14** 15B  17F  18C  19A**  19F** 20 22F  23F**
33F 
**These serotypes most frequently cause drug-resistant pneumococcal
infections

CLINICAL PHARMACOLOGY 

Pneumococcal infection is a leading cause of death throughout the
world and a major cause of pneumonia, 
bacteremia, meningitis, and otitis media. Strains of
drug-resistant _S. pneumoniae_ have become increasingly 
common in the United States and in other parts of the world. In some
areas as many as 35% of 
pneumococcal isolates have been reported to be resistant to
penicillin. Many penicillin-resistant 
pneumococci are also resistant to other antimicrobial drugs (e.g.,
erythromycin, trimethoprim-
sulfamethoxazole and extended-spectrum cephalosporins),
the

Αρχείο Π.Χ.Π.

S-SGPI-V110-I-022016
PHYSICIANS CIRCULAR
Injection
PNEUMOVAX® 23
(pneumococcal vaccine, polyvalent, MSD)
PNEUMOVAX 23 (pneumococcal vaccine, polyvalent, MSD), is a sterile,
liquid vaccine for intramuscular or
subcutaneous injection. It consists of a mixture of highly purified
capsular polysaccharides from the 23 most
prevalent or invasive pneumococcal types of
Streptococcus pneumoniae
, including the six serotypes that
most frequently cause invasive drug-resistant pneumococcal infections
among children and adults in the
United States (see Table 1). The 23-valent vaccine accounts for at
least 90% of pneumococcal blood
isolates and at least 85% of all pneumococcal isolates from sites
which are generally sterile as determined
by ongoing surveillance of United States data.
PNEUMOVAX 23
is
manufactured
according
to
methods
developed
by
the
MERCK
RESEARCH
LABORATORIES. Each 0.5 mL dose of vaccine contains 25 mcg of each
polysaccharide type dissolved in
isotonic saline solution containing 0.25% phenol as a preservative.
Table 1
23 Pneumococcal Capsular Types Included in PNEUMOVAX 23
Danish Nomenclature
Pneumococcal Types
1
2
3
4
5
6B**
7F
8
9N
9V**
10A
11A
12F
14**
15B
17F
18C
19A**
19F**
20
22F
23F**
33F
**These serotypes most frequently cause drug-resistant pneumococcal
infections
CLINICAL PHARMACOLOGY
Pneumococcal infection is a leading cause of death throughout the
world and a major cause of pneumonia,
bacteremia, meningitis, and otitis media. Strains of drug-resistant
S. pneumoniae
have become increasingly
common in the United States and in other parts of the world. In some
areas as many as 35% of
pneumococcal
isolates
have
been
reported
to
be
resistant
to
penicillin.
Many
penicillin-resistant
pneumococci
are
also
resistant
to
other
antimicrobial
drugs
(e.g.,
erythromycin,
trimethoprim-
sulfamethoxazole
and
extended-spectrum
cephalosporins),
therefore
emphasizing
the
importance
of
vaccine prophylaxis against pneumococcal disease.
Epidemiology
Pneumococcal infection causes approximately 40,000 deaths annually in
th